AMPK Activator Compound 991 Extends Lifespan Across Three Species

AMPK — AMP-activated protein kinase — is a fundamental cellular energy sensor that responds to low energy states by promoting metabolic efficiency, autophagy, and stress resistance. It has long been considered a promising longevity target, partly because indirect activators like metformin (which inhibits mitochondrial complex I) extend lifespan in multiple organisms. However, metformin's pleiotropic effects make it difficult to attribute longevity benefits specifically to AMPK. This study addresses that ambiguity head-on.

Researchers administered compound 991, a potent and selective direct AMPK activator, to three evolutionarily distinct model organisms: the fission yeast Schizosaccharomyces pombe, the nematode Caenorhabditis elegans, and the fruit fly Drosophila melanogaster. All three showed significant lifespan extension, providing robust cross-species validation of AMPK's role in aging biology.

In mice, compound 991 treatment did not directly test lifespan but instead induced a proteomic profile characterized by changes consistent with pro-longevity signaling. This suggests the mechanism may translate to mammals and warrants further investigation in longer mammalian lifespan studies.

The key advance here is specificity. By using a direct activator rather than an indirect one, the researchers can more confidently conclude that AMPK activation itself — not collateral metabolic disruption — drives the longevity benefit. This is an important proof-of-principle that strengthens AMPK's candidacy as a pharmacological longevity target.

Caveats remain: the study relies on short-lived invertebrate models and mouse proteomic data rather than mammalian survival endpoints. Compound 991 is a research tool, not a clinical drug, and translation to humans will require safety profiling, bioavailability optimization, and long-term mammalian lifespan studies. Nonetheless, this work meaningfully advances the AMPK-aging field.